Ovarian Cancer Screening Trial
Early detection of ovarian cancer greatly increases survival rates. This study will explore if the CA-125 level is an accurate detector of early stage ovarian cancer.
If you are a woman and want to considered for the trial here are the requirements:
- 50 to 75 years of age
- at least one year post-menopausal
- have at least one ovary
- are willing to have blood draw for a CA-125 test at least once a year
- are cancer free, or have been cancer/treatment free for at least 12 months
For more information about the Ovarian Cancer Screening Trial please contact the UnityPoint Health-Des Moines Office of Research at 515-241-6727.
FDA Approved Studies
The Office of Research has been involved with a variety of inpatient and outpatient studies since the office was established over 15 years ago. Many of the drugs and devices studied have received FDA approval. Following are a few of the FDA approved drugs/devices studied at UnityPoint Health:
Havrix™, dabigatran, alvimopan, micafungin, cinacalcet, omalizumab, dimethyl fumarate, telavancin, everolimus, methylnaltrexone, RotaTeq™, Endurant Endograft Stent™, Aimovig and the INCRAFT™ AAA Stent Graft System.
All studies help answer important clinical questions and help lead us down the path to improved healthcare for the patients we serve.